• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

碳酸钙给药时间(进餐前或进餐期间)对维持性血液透析患者高磷血症控制的作用

[Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].

作者信息

Séchet A, Abighanem O, Said S, Rasombololona M, Morinière P, Brazier M, Fournier A

机构信息

Service de néphrologie, CHU Sud, Amiens.

出版信息

Nephrologie. 1999;20(4):209-12.

PMID:10480153
Abstract

UNLABELLED

A study has claimed that at equal elemental calcium dose, CaCO3 was not less but equally efficient in controlling predialysis hyperphosphatemia as calcium acetate provided both calcium salts were given five minutes before the meals instead of during the meals because the higher acidity of a fasting gastric juice would allow a better dissociation of CaCO3. To examine the point that CaCO3 is more efficient if it is taken five minutes before compared to during the meal, we performed a two month randomised cross-over trial in twelve reliable and stable patients maintained on chronic hemodialysis while their treatment and diet remained constant. Comparison of the plasma concentrations measured during the two modes of administration showed no significant difference in creatinine, urea, bicarbonate, intact-PTH. Mean (+/- SD) plasma PO4 was significantly higher (1.93 +/- 0.50 versus 1.72 +/- 0.40 mmol/l; p = 0.02) whereas corrected plasma Ca was significantly lower (2.30 +/- 0.15 versus 2.38 +/- 0.17 mmol/l; p = 0.01) when CaCO3 was given before the meals than during the meals.

CONCLUSIONS

a) administration of CaCO3 before the meal decreases its efficiency in controlling hyperphosphatemia since plasma PO4 was actually slightly higher with this timing of administration; b) administration of CaCO3 before the meal is associated with significantly lower plasma corrected calcium suggesting a smaller absorption of calcium which may be an advantage but only in hypercalcemic patients; c) there is no reason other than the prevention of its hypercalcemic effect to recommend the administration of CaCO3 just before the meals than during the meals.

摘要

未标注

一项研究称,在元素钙剂量相等的情况下,碳酸钙在控制透析前高磷血症方面并不逊色,而是与醋酸钙同样有效,前提是两种钙盐均在餐前五分钟而非餐中服用,因为空腹胃液的较高酸度会使碳酸钙更好地解离。为了验证与餐中服用相比,碳酸钙在餐前五分钟服用是否更有效,我们对12例维持性慢性血液透析的可靠且稳定的患者进行了为期两个月的随机交叉试验,同时他们的治疗和饮食保持不变。两种给药方式下测得的血浆浓度比较显示,肌酐、尿素、碳酸氢盐、完整甲状旁腺激素无显著差异。当碳酸钙在餐前服用时,平均(±标准差)血浆磷显著更高(1.93±0.50对1.72±0.40 mmol/L;p = 0.02),而校正后血浆钙显著更低(2.30±0.15对2.38±0.17 mmol/L;p = 0.01)。

结论

a)餐前服用碳酸钙会降低其控制高磷血症的效率,因为这种给药时间下血浆磷实际上略高;b)餐前服用碳酸钙与显著更低的校正后血浆钙相关,表明钙吸收减少,这可能是一个优势,但仅在高钙血症患者中;c)除了预防高钙血症作用外,没有理由推荐在餐前而非餐中服用碳酸钙。

相似文献

1
[Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].碳酸钙给药时间(进餐前或进餐期间)对维持性血液透析患者高磷血症控制的作用
Nephrologie. 1999;20(4):209-12.
2
Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis.
Artif Organs. 1998 Jul;22(7):564-8. doi: 10.1046/j.1525-1594.1998.06199.x.
3
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
4
Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.慢性间歇性血液透析患者中的氢氧化铝、碳酸钙和醋酸钙
Clin Nephrol. 1996 Feb;45(2):111-9.
5
[Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia].
Nephrologie. 1991;12(4):193-7.
6
[Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate in the control of hyperphosphatemia in patients on maintenance hemodialysis].[奥美拉唑对胃酸分泌的抑制作用及碳酸钙在维持性血液透析患者高磷血症控制中的疗效]
Nephrologie. 1999;20(4):213-6.
7
Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?司维拉姆与碳酸钙联合使用是否会改变血磷的控制情况?
Ther Apher Dial. 2010 Apr;14(2):172-7. doi: 10.1111/j.1744-9987.2009.00748.x.
8
Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.泮托拉唑抑制胃酸对血液透析患者碳酸钙作为磷酸盐结合剂疗效的影响。
Nephrology (Carlton). 2012 Jul;17(5):458-65. doi: 10.1111/j.1440-1797.2012.01604.x.
9
Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis.奥美拉唑对胃酸分泌的抑制作用及碳酸钙对慢性血液透析患者高磷血症的控制效果。
Artif Organs. 1998 Jul;22(7):569-73. doi: 10.1046/j.1525-1594.1998.06200.x.
10
Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
Nephron. 1989;52(2):125-32. doi: 10.1159/000185614.

引用本文的文献

1
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常(CKD-MBD)的磷结合剂。
Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
2
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常(CKD-MBD)的磷结合剂。
Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3.